{
    "nct_id": "NCT04708041",
    "official_title": "A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen With Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared With a Standard 3-dose Regimen in 16- to 26-Year Old Women",
    "inclusion_criteria": "Boys and Girls 9 to 15 Years:\n\n- Must not have had coitarche and does not plan on becoming sexually active during the vaccination period\n\nWomen 16 to 26 Years:\n\n* Has never had a Papanicolaou (Pap) test or only had normal Pap test results\n* A lifetime history of 0 to 4 male and/or female sexual partners\n\nCohort 0 Participants:\n\n- Received 1 dose of 9vHPV vaccine at least 1 year prior to enrollment and did not receive a second dose of any HPV vaccine\nHealthy volunteers allowed\nMust have minimum age of 9 Years\nMust have maximum age of 26 Years",
    "exclusion_criteria": "All Participants:\n\n* Known allergy to any vaccine component\n* History of severe allergic reaction that required medical intervention\n* Thrombocytopenia or any coagulation disorder\n* Females only: participant is pregnant or expecting to donate eggs during day 1 through month 7\n* Currently immunocompromised, or been diagnosed with immunodeficiency\n* Had a splenectomy\n* Receiving or has received immunosuppressive therapies within the last year\n* Received any immunoglobulin product or blood-derived product within 3 months\n* Has received more than 1 dose of an HPV vaccine (Cohort 0)\n* Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial (Cohorts 1-5)",
    "miscellaneous_criteria": ""
}